Genetic Heterogeneity, Therapeutic Hurdle Confronting Sorafenib and Immune Checkpoint Inhibitors in Hepatocellular Carcinoma

Genetic Heterogeneity, Therapeutic Hurdle Confronting Sorafenib and Immune Checkpoint Inhibitors in Hepatocellular Carcinoma

Despite the latest advances in hepatocellular carcinoma (HCC) screening and treatment modalities, HCC is still representing a global burden. Most HCC patients present at later stages to an extent that conventional curative options are ineffective. Hence, systemic therapy represented by the tyrosine...

Full description

Bibliographic Details
Main Authors: Sara M. Atwa, Margarete Odenthal, Hend M. El Tayebi
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Cancers
Subjects:
ANGPT-2
cell death
drug resistance
drug transport
eNOS
genetic variants
Online Access:https://www.mdpi.com/2072-6694/13/17/4343

Internet

https://www.mdpi.com/2072-6694/13/17/4343

Similar Items